Viewing Study NCT03002103

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:45 PM
Ignite Modification Date: 2026-02-21 @ 10:11 PM
Study NCT ID: NCT03002103
Status: SUSPENDED
Last Update Posted: 2023-04-26
First Post: 2016-12-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
Sponsor: SynCore Biotechnology Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Triple-Negative Breast Cancer View
Keywords: